Bioventix PLC (AIM:BVXP)
2,025.00
-25.00 (-1.22%)
Nov 4, 2026, 4:54 PM GMT
Bioventix Revenue
In the fiscal year ending June 30, 2026, Bioventix had annual revenue of 12.97M GBP, down -1.10%. Bioventix had revenue of 6.81M in the half year ending June 30, 2026, a decrease of -1.71%. That makes Bioventix the 34,621st largest company in the world by revenue and 685th in the United Kingdom.
Revenue
12.97M
Revenue Growth
-1.10%
P/S Ratio
8.16
Revenue / Employee
1.08M
Employees
12
Market Cap
105.80M
Revenue by Segment
Fiscal year ended Jun 30, 2026 See the full Bioventix breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 12.97M | -144.13K | -1.10% |
| Jun 30, 2025 | 13.12M | -490.72K | -3.61% |
| Jun 30, 2024 | 13.61M | 790.36K | 6.17% |
| Jun 30, 2023 | 12.82M | 1.10M | 9.36% |
| Jun 30, 2022 | 11.72M | 788.68K | 7.22% |
| Jun 30, 2021 | 10.93M | 617.01K | 5.98% |
| Jun 30, 2020 | 10.31M | 1.02M | 11.02% |
| Jun 30, 2019 | 9.29M | 538.42K | 6.15% |
| Jun 30, 2018 | 8.75M | 1.51M | 20.78% |
| Jun 30, 2017 | 7.25M | 1.73M | 31.33% |
| Jun 30, 2016 | 5.52M | 1.18M | 27.32% |
| Jun 30, 2015 | 4.33M | 1.63M | 60.11% |
| Jun 30, 2013 | 2.71M | 322.47K | 13.53% |
| Jun 30, 2012 | 2.38M | 410.43K | 20.80% |
| Jun 30, 2011 | 1.97M | 395.38K | 25.05% |
| Jun 30, 2010 | 1.58M | -69.52K | -4.22% |
| Jun 30, 2009 | 1.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IXICO | 7.28M |
| PureTech Health | 4.80M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| Arecor Therapeutics | 890.00K |
| 4basebio | 781.00K |
| Avacta Group | 113.00K |
Bioventix News
- 9 days ago - Bioventix Annual report: H2 2026 - Filings
- 9 days ago - Bioventix Slides: H2 2026 - Filings
- 7 months ago - Bioventix Slides: H1 2026 - Filings
- 7 months ago - Bioventix Quarterly report: H1 2026 - Filings
- 1 year ago - AIM Market Roundup: Angle, Coyngar, Light Science Technologies - The Armchair Trader